1. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy.
- Author
-
Zambelli, Alberto, Cazzaniga, Marina, La Verde, Nicla, Munzone, Elisabetta, Antonazzo, Ippazio Cosimo, Mantovani, Lorenzo Giovanni, Di Cosimo, Serena, Mancuso, Anna, Generali, Daniele, and Cortesi, Paolo Angelo
- Subjects
NEOADJUVANT chemotherapy ,HER2 positive breast cancer ,BREAST cancer ,ECONOMIC impact ,DIRECT costing ,HORMONE receptor positive breast cancer - Abstract
Clinical trials confirmed the beneficial effects of adding pertuzumab (P) to the combination of trastuzumab-chemotherapy (TC) in the (neo)adjuvant setting of high-risk HER2-positive early breast cancer (HER2+BC). We evaluated the clinical, economic and societal impact of adding pertuzumab to neoadjuvant TC combination (TPC) in Italy. A cost-consequence analysis comparing TPC vs. TC was performed developing a cohort-based multi-state Markov model to estimate the clinical, societal and economic impact of the neoadjuvant therapy of TPC versus TC in HER2+BC at high-risk of recurrence. The model works on a cycle length of 1 month and 5-years-time horizon. Literature review-based data were used to populate the model. The following clinical and economic outcomes were estimated: cumulative incidence of loco-regional/distant recurrences, life of years and QALY and both direct and indirect costs (€). Finally, sensitivity analyses were performed. TPC was associated with a 75,630 € saved of direct costs. Specifically, it was associated with an initial increase of treatment costs (+4.8%) followed by reduction of recurrence management cost (−20.4%). TPC was also associated with an indirect cost reduction of 1.40%, as well as decreased incidence of distant recurrence (−20.14%), days of work lost (−1.53%) and days lived with disability (−0.50%). Furthermore, TPC reported 10,47 QALY gained (+2.77%) compared to TC. The probability to achieve the pathological complete response (pCR) was the parameter that mostly affected the results in the sensitivity analysis. Our findings suggested that TPC combination could be a cost-saving option in patients with HER2+BC at high-risk of recurrence. • TPC in the (neo)adjuvant setting is an effective treatment in high-risk HER2-positive early breast cancer. • TPC in the (neo)adjuvant setting is reimbursed in many European countries but not in Italy. • In our analysis, TPC was associated with a 124,956 € saved per 100 treated patients over 5-year time horizon compared to TC. • TPC showed a reduction of distant recurrence (−20.14%), days of work lost (−1.53%) and days lived with disability (−0.50%). • TPC showed a cost-saving profile in patients with HER2-positive early BC at high-risk of recurrence compared to TC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF